|Caspase-4 (Cell-free assay)||Caspase-1 (Cell-free assay)|
|<0.6 nM(Ki)||0.8 nM(Ki)|
|In vitro||DMSO||100 mg/mL heating (196.46 mM)|
|Water||<1 mg/mL (<1 mM)|
|Ethanol||100 mg/mL heating (196.46 mM)|
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.1 mM||19.65 mL||98.23 mL||196.46 mL|
|0.5 mM||3.93 mL||19.65 mL||39.29 mL|
|1 mM||1.96 mL||9.82 mL||19.65 mL|
|5 mM||0.39 mL||1.96 mL||3.93 mL|
*The above data is based on the productmolecular weight 509.0 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|MECHANISM OF ACTION||Inhibitor|
|Storage||at -20°C 3 years Powder|
Z-WEHD-FMK is a synthetic peptide that irreversibly inhibits caspase-5 and related caspase activity.
Z-LEHD-FMK is a synthetic peptide that irreversibly inhibits caspase-9 and related caspase activity.
PETCM is an activator of caspase-3 and a stimulator of apoptosome formation in HeLa cell cytosols.
Nivocasan is a novel caspase-inhibitor has demonstrated hepatoprotective activity in fibrosis/apoptosis animal models.